Evidence map›Paper›PMID 35768637›Full record

ArticleMolecular psychiatry2022

Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression.

Amaryllis A Tsiknia, Steven D Edland, Erin E Sundermann, Emilie T Reas, James B Brewer, Douglas Galasko, Sarah J Banks, Alzheimer’s Disease Neuroimaging Initiative

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 3 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 3 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Sex differences inFrontiers in dementia · 2025
    Pooled it
  3. Pooled it
  4. Article
  5. Considerations in Alzheimer's Disease in Women.Current neurology and neuroscience reports · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  11. Article
  12. Diabetes, hyperglycemia, and ATN blood biomarkers in Hispanic/Latino populations: SOL-INCA study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  13. Article
  14. Review
  15. Sex differences in Alzheimer's disease plasma biomarker levels and clinical utility.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Amaryllis A TsikniaDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, 92093, USA.
Steven D EdlandDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, 92093, USA.
Erin E SundermannDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, 92093, USA.
Emilie T ReasDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, 92093, USA.
James B BrewerDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, 92093, USA.
Douglas GalaskoDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, 92093, USA.
Sarah J BanksDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, 92093, USA. sbanks@health.ucsd.edu.ORCID http://orcid.org/0000-0001-7536-2370
Alzheimer’s Disease Neuroimaging Initiative
University of California San Diego · USUC San Diego Health System · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Steven Dyal Edland · 2019 to 2026
$34.9M
Sex-specific cognitive expression and risk in preclinical Alzheimer's diseaseR01AG066088 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BANKS, SARAH · 2019 to 2023
$3.9M
Sex Differences in the Clinical Expression of Alzheimer's Disease Neuropathology and Their Underlying Biological MechanismsR01AG074221 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUNDERMANN, ERIN ELIZABETH · 2021 to 2025
$2.7M
UCSD Leading the Advancement of Underrepresented Neuroscientists for Change (LAUNCH) Faculty Development ProgramR25NS117367 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Victoria B Risbrough, Joann Trejo · 2020 to 2026
$1.6M
NIA NIH HHS P30 AG062429NIA NIH HHS R01 AG066088NIA NIH HHS R01 AG074221NIA NIH HHS U01 AG024904NINDS NIH HHS R25 NS117367
6 · The paper itself

Abstract

Studies have shown that women on the Alzheimer's disease (AD) continuum have more pathological tau in the brain and cerebrospinal fluid (CSF), than men. Some studies have found that higher levels of tau biomarkers are more strongly associated with clinical AD, cognitive decline and neurodegeneration in women than in men. Despite major developments in the use of plasma tau phosphorylated at threonine 181 (p-tau181) as an AD biomarker, it is unknown whether these sex differences apply to plasma p-tau181. In 1060 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants (47% women, 73.8 ± 7.6 years old), we examined sex differences in plasma p-tau181 levels and their association with other biomarkers, cognitive decline and incident AD. Linear regressions tested for an effect of sex on plasma p-tau181 levels and for plasma p-tau181 × sex interactions on CSF p-tau181, as well as entorhinal cortex tau, cortical amyloid-β (Aβ) deposition, and brain glucose metabolism, quantified using PET imaging. Linear mixed effects models tested for a sex × baseline plasma p-tau181 interaction on change in cognition over time. Finally, Cox models tested for a sex × plasma p-tau181 interaction on the risk of AD dementia in participants who were free of dementia at baseline. Despite similar plasma p-tau181 levels between sexes, women had lower brain glucose metabolism, greater brain Aβ and entorhinal cortex tau deposition, higher CSF p-tau181 and faster cognitive decline in relation to higher baseline plasma p-tau181 levels compared with men. Among Aβ positive, dementia-free participants, women had higher rates of incident AD dementia associated with increasing baseline plasma p-tau181 levels, relative to men. Our results suggest that sex may impact the clinical interpretation of plasma p-tau181 concentrations. If replicated, these findings could have important implications for the use of plasma p-tau181 as an accessible AD biomarker and screening tool for preventive and therapeutic clinical trials.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersDisease ProgressionFemaleGlucoseHumansMaleSex Characteristicstau ProteinsThreonineAmyloid beta-PeptidesBiomarkersGlucosetau ProteinsThreonine

Identifiers

PMID35768637
PMCPMC9718670
OpenAlexW4283709625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.